CareLit Fachartikel

Once-daily tiotropium Respimat add-on to ICS ± LABA improves control across asthma severities

O Schmidt, JM FitzGerald, H Kerstjens, P Paggiaro, K Ohta, M Ichinose, P Moroni-Zentgraf, M Engel, H Schmidt, E Bateman · Pneumologie · 2015 · Heft 02

Dokument
1053518
CareLit-ID
Jahr
2015
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
O Schmidt, JM FitzGerald, H Kerstjens, P Paggiaro, K Ohta, M Ichinose, P Moroni-Zentgraf, M Engel, H Schmidt, E Bateman
Ausgabe
Heft 02 / 2015
Seiten
–
Erschienen: 2015-02-04 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0035-1544685

Zusammenfassung

Background: Tiotropium Respimat added to ICS±LABA has been investigated across asthma severities. We present ACQ-7 responses from six Phase III randomised, double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Methods: Two 48-wk trials (PrimoTinA, NCT00772538/6984): 5µg added to ICS (≥800µg budesonide or equivalent [bud or eq])+LABA; two 24-wk trials (MezzoTinA, NCT01172808/2821): 5/2.5µg added to ICS (400 – 800µg bud or eq); 12-wk trial (GraziaTinA, NCT01316380): 5/2.5µg added to ICS (200 – 400µg bud or eq); 52-wk trial (CadenTinA, NCT01340209): 5/2.5µg added to ICS (400 –…

Schlagworte

Pneumologie